Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21386690 | 0.72 | — | — | |
| SCHEMBL21386595 | 0.71 | GAA (0.36) | GAAPRKDCTDP1KDM4EALDH1A1 | |
| SCHEMBL21386677 | 0.70 | GAA (0.33) | GAAERN1TDP1KDM4EALDH1A1 | |
| SCHEMBL20094055 | 0.70 | GAA (0.39) | GAAERN1TDP1KDM4EALDH1A1 | |
| SCHEMBL1359479 | 0.70 | ALDH1A1 (0.50) | GAAERN1PRKDCTDP1KDM4E | |
| SCHEMBL21756585 | 0.70 | KCNQ3 (0.42) | TDP1KDM4EALDH1A1 | |
| SCHEMBL21386607 | 0.67 | CYP1A1 (0.52) | GAAKDM4EALDH1A1 | |
| SCHEMBL16994765 | 0.66 | GAA (0.43) | GAAERN1PRKDCTDP1KDM4E | |
| SCHEMBL21386687 | 0.66 | GAA (0.33) | GAAPRKDCKDM4EALDH1A1NFE2L2 | |
| SCHEMBL12348450 | 0.64 | GAA (0.44) | GAATDP1KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2021-05-18 | — | — | US | disclosed |
| EP-3543227-B1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3543227-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Guangdong Zhongsheng Pharmaceutical Co., Ltd (CN) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | GAA 768/4885ERN1 4107/4885PRKDC 2124/4885 |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FGFR4, FGFR1, FGFR2 | GAA 768/4885ERN1 4107/4885PRKDC 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.